文献速递皮肤肿瘤

系统治疗对原发灶不明转移性黑色素瘤的影响:来自法国多中心前瞻性队列MELBASE的研究

Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort.
PubMed 文献 · J Am Acad Dermatol · 2022-12-19

基于法国MelBase前瞻性数据库,纳入2013年3月至2021年6月接受一线免疫治疗、靶向治疗或化疗的晚期黑色素瘤患者1882例,其中原发灶不明转移性黑色素瘤(MUP)265例(14.1%)。MUP组基线预后因素更差,但两组无进展生存和总生存无显著差异(P=.73和P=.93),治疗相关毒性发生率和严重程度亦无显著差异,且不受治疗类型影响。

要点

  • 晚期MUP占全部晚期黑色素瘤的14.1%(265/1882),其基线预后因素较原发灶已知的皮肤黑色素瘤(cMKP)更差。
  • MUP与cMKP的无进展生存和总生存无显著差异(P=.73和P=.93),治疗相关毒性发生率和严重程度亦无显著差异。
  • 尽管MUP基线预后因素较差,其从新型治疗中的获益与cMKP相当,应按相似策略管理。

核心结论

  • 尽管MUP患者基线预后因素较差,他们从新型治疗中的获益与cMKP患者相当,应按相似策略管理。

研究设计与样本

  • 基于法国全国性MelBase前瞻性数据库,纳入2013年3月至2021年6月接受一线免疫治疗、靶向治疗或化疗的晚期黑色素瘤患者1882例,其中MUP 265例(14.1%),cMKP为分期匹配的原发灶已知皮肤黑色素瘤患者;采用多因素和倾向性评分分析。

主要发现

  • 1882例患者中265例(14.1%)为晚期MUP,MUP组较cMKP组更常见不利的初始预后因素。
  • MUP组与cMKP组的无进展生存无显著差异(P=.73),总生存亦无显著差异(P=.93)。
  • 无论治疗类型如何,两组的治疗相关毒性发生率和严重程度均无显著差异。

临床怎么用

  • 作者认为,MUP患者应按与cMKP相似的策略进行管理。

局限性

  • 参与中心未记录MUP的标准诊断标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical outcomes of advanced melanoma of unknown primary (MUP) in the era of novel therapies have been scarcely studied. OBJECTIVE: To investigate the efficacy and safety of systemic treatments in patients with advanced MUP compared to patients with stage-matched melanoma of known cutaneous primary (cMKP). METHODS: Based on the nationwide MelBase prospective database, this study included advanced melanoma patients treated from March 2013 to June 2021 with first-line immunotherapies, targeted therapies, or chemotherapy. Co-primary outcomes were progression-free survival and overall survival. Secondary outcome was treatment-related toxicities. Multivariate and propensity score analyses were performed. RESULTS: Of 1882 patients, 265 (14.1%) had advanced MUP. Patients with advanced MUP displayed more often unfavorable initial prognostic factors than those with cMKP. Progression-free and overall survival did not differ significantly between the groups (P = .73 and P = .93, respectively), as well as treatment-related toxicity rate and severity, regardless of treatment type. LIMITATIONS: No record of standard diagnostic criteria of MUP used in the participating centers. CONCLUSIONS: Although patients with MUP had less favorable baseline prognostic factors, they benefited from the novel therapies as much as those with cMKP. They should be managed according to similar strategies.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Rousset P, Dalle S, Mortier L, et al. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort. J Am Acad Dermatol. 2022. PMID: 36543626. doi:10.1016/j.jaad.2022.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。